Literature DB >> 34015133

Beware of Biases in Observational Studies on Anti-Spike Monoclonal Antibodies.

Giuseppe Lapadula1, Davide Paolo Bernasconi2, Alessandro Soria1, Maria Grazia Valsecchi2, Paolo Bonfanti1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34015133      PMCID： PMC9012953          DOI： 10.1093/cid/ciab467

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

2.  'Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness' - Author's reply.

Authors:  Martin Wolkewitz; Maja von Cube; Oksana Martinuka
Journal:  Clin Microbiol Infect       Date:  2021-05-15       Impact factor: 13.310

3.  Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.

Authors:  Rebecca N Kumar; En-Ling Wu; Valentina Stosor; William J Moore; Chad Achenbach; Michael G Ison; Michael P Angarone
Journal:  Clin Infect Dis       Date:  2022-01-07       Impact factor: 9.079

4.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.

Authors:  David M Weinreich; Sumathi Sivapalasingam; Thomas Norton; Shazia Ali; Haitao Gao; Rafia Bhore; Bret J Musser; Yuhwen Soo; Diana Rofail; Joseph Im; Christina Perry; Cynthia Pan; Romana Hosain; Adnan Mahmood; John D Davis; Kenneth C Turner; Andrea T Hooper; Jennifer D Hamilton; Alina Baum; Christos A Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Anita Kohli; Yessica Sachdeva; Ximena Graber; Bari Kowal; Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos
Journal:  N Engl J Med       Date:  2020-12-17       Impact factor: 91.245

5.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Authors:  Robert L Gottlieb; Ajay Nirula; Peter Chen; Joseph Boscia; Barry Heller; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Princy Kumar; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Michael Durante; Gerard Oakley; Andrew E Schade; Timothy R Holzer; Philip J Ebert; Richard E Higgs; Nicole L Kallewaard; Janelle Sabo; Dipak R Patel; Paul Klekotka; Lei Shen; Daniel M Skovronsky
Journal:  JAMA       Date:  2021-02-16       Impact factor: 56.272

6.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

Authors:  Peter Chen; Ajay Nirula; Barry Heller; Robert L Gottlieb; Joseph Boscia; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Lei Shen; Michael Durante; Gerard Oakley; Andrew E Schade; Janelle Sabo; Dipak R Patel; Paul Klekotka; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2020-10-28       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.